The highest vs lowest quartile of serum oxalate levels were significantly associated with 40% and 62% increases risks for serious cardiovascular events and sudden cardiac death, respectively.
Among the patients with high-risk diabetes in the trial, 21.8% had both a history of cardiovascular disease and current kidney disease.
Patients with hyperglycemia had higher cumulative probability of mortality, independent of preexisting diabetes
T2DM risk reduced by 39 percent for those with high adherence to antimalarial therapy for managing lupus.
New findings suggest that it may be possible to direct interventions toward frailty to ameliorate urolithiasis risk in patients with diabetes.
In a study of patients with type 2 diabetes at high cardiovascular (CV) risk, metformin use decrease the risk of all-cause mortality but had no significant effect on a composite end point of CV death, MI, or ischemic stroke.
Protective effect is driven largely by a sustained 40% decrease in estimate glomerular filtration rate to below 60 mL/min/1.73 m2.
If approved, canagliflozin would be the first drug in almost 20 years indicated to treat CKD in patients with type 2 diabetes when added to current standard of care, according to the drug’s maker.
The percentage decline in estimated glomerular filtration rate over an 8-year period was greater among those with vs without diabetes across all quintiles of protein intake.
Delayed-release Niacin may be beneficial to patients with prediabetes and type 2 diabetes.
